Flunoxaprofen

Title: Flunoxaprofen
CAS Registry Number: 66934-18-7
CAS Name: (aS)-2-(4-Fluorophenyl)-a-methyl-5-benzoxazoleacetic acid
Manufacturers' Codes: RV-12424
Trademarks: Priaxim (Ravizza)
Molecular Formula: C16H12FNO3
Molecular Weight: 285.27
Percent Composition: C 67.36%, H 4.24%, F 6.66%, N 4.91%, O 16.83%
Literature References: Nonsteroidal anti-inflammatory. Prepn of racemate: D. Evans et al., DE 2324443; eidem, US 3912748 (1973, 1975 both to Lilly). Prepn of racemate and anti-inflammatory activity: D. W. Dunwell et al., J. Med. Chem. 18, 53-58 (1975). Improved process for prepn of racemate and enantiomers: F. Mauri, R. Signorini, BE 877887; eidem, US 4304918 (1979, 1981 both to Ravizza); R. Signorini, A. Verga, DE 3325672 (1984 to Ravizza). HPLC determn of enantiomers in body fluids: S. Pedrazzini et al., J. Chromatogr. 415, 214 (1987). Prophylactic and therapeutic treatment of asthma and other immediate hypersensitivity diseases: W. Dawson, US 4416892 (1983 to Lilly).
Properties: Crystals from acetone-water or acetic acid, mp 162-164°. [a]D20 +50° (c = 2% in DMF). LD50 orally in mice: ~1200 mg/kg (Dunwell).
Melting point: mp 162-164°
Optical Rotation: [a]D20 +50° (c = 2% in DMF)
Toxicity data: LD50 orally in mice: ~1200 mg/kg (Dunwell)
Therap-Cat: Anti-inflammatory.
Keywords: Anti-inflammatory (Nonsteroidal); Arylpropionic Acid Derivatives.
Fluoboric Acid Fluocinolone Acetonide Fluocortin Butyl Fluocortolone Fluometuron

Flunoxaprofen
Flunoxaprofen.png
Flunoxaprofen-space-filling.png
Systematic (IUPAC) name
(2S)-2-[2-(4-fluorophenyl)-1,3-benzoxazol-5-yl]propanoic acid
Clinical data
Legal status  ?
Identifiers
CAS number 66934-18-7 YesY
ATC code G02CC04 M01AE15
PubChem CID 68869
UNII UKU5U19W9M YesY
KEGG D07219 YesY
ChEBI CHEBI:76154 N
ChEMBL CHEMBL1614641 N
Chemical data
Formula C16H12FNO3 
Mol. mass 285.269783 g/mol
 N (what is this?)  (verify)

Flunoxaprofen, also known as Priaxim, is a chiral non-steroidal anti-inflammatory drug. It is closely related to Naproxen, which is also an NSAID. Flunoxaprofen has been shown to significantly improve the symptoms of osteoarthritis and rheumatoid arthritis. The clinical use of flunoxaprofen has ceased due to concerns of potential hepatotoxicity.